Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation

Circulating levels of fibroblast growth factor-21 (FGF21) start increasing in patients with chronic kidney disease (CKD) since early stages during the cause of disease progression. FGF21 is a liver-derived hormone that induces responses to stress through acting on hypothalamus to activate the sympat...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Toshihiro, Shiizaki, Kazuhiro, Miura, Yutaka, Matsui, Masahiro, Kosaki, Keisei, Mori, Shoya, Yamagata, Kunihiro, Maeda, Seiji, Kishi, Takuya, Usui, Naoki, Yoshida, Masahide, Onaka, Tatsushi, Mizukami, Hiroaki, Kaneda, Ruri, Karasawa, Kazunori, Nitta, Kosaku, Kurosu, Hiroshi, Kuro-o, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917750/
https://www.ncbi.nlm.nih.gov/pubmed/31848393
http://dx.doi.org/10.1038/s41598-019-55643-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6917750/
https://www.ncbi.nlm.nih.gov/pubmed/31848393
http://dx.doi.org/10.1038/s41598-019-55643-4

Ejemplares similares